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Abstract: The conserved nuclease-helicase DNA2 has been linked to mitochondrial myopathy,
Seckel syndrome, and cancer. Across species, the protein is indispensable for cell proliferation.
On the molecular level, DNA2 has been implicated in DNA double-strand break (DSB) repair,
checkpoint activation, Okazaki fragment processing (OFP), and telomere homeostasis. More recently,
a critical contribution of DNA2 to the replication stress response and recovery of stalled DNA
replication forks (RFs) has emerged. Here, we review the available functional and phenotypic data
and propose that the major cellular defects associated with DNA2 dysfunction, and the links that exist
with human disease, can be rationalized through the fundamental importance of DNA2-dependent
RF recovery to genome duplication. Being a crucial player at stalled RFs, DNA2 is a promising target
for anti-cancer therapy aimed at eliminating cancer cells by replication-stress overload.
Keywords: DNA replication stress; chromosome stability; stalled replication fork; replication fork rever-
sal; chicken-foot structure; replication fork recovery; chromosome underreplication; anaphase bridge;
DNA end-resection; Okazaki fragment processing
1. Introduction
DNA2 was first identified in Saccharomyces cerevisiae in a screen for candidate DNA
replication factors (reflected in the budding yeast name DNA synthesis defective 2) [1,2].
The human homolog is known as DNA replication ATP-dependent helicase/nuclease
DNA2 [3–5]. Across organisms, DNA2 is required for cellular proliferation and organismal
survival [6–9]. In human, DNA2 mutations result in the primordial dwarfism disorder
Seckel syndrome [10,11] and have been linked to mitochondrial myopathy [12–14]. Deple-
tion of the gene product Dna2 in budding yeast [15] or DNA2 in human cells [16,17] has
been demonstrated to result in chromosomal instability.
Dna2DNA2
′
s dual enzymatic activities reside within a RecB-like nuclease domain
with single-stranded DNA (ssDNA) specificity and a superfamily 1 helicase domain with
5′-to-3′ translocation polarity [5,6,18,19] (Figure 1). The nuclease and helicase activities
of Dna2DNA2 are closely linked and have been implicated in multiple DNA replication
and DNA repair functions. As we will discuss in detail below, these include Okazaki
fragment processing (OFP) during lagging strand DNA synthesis, the processing and
recovery of stalled DNA replication forks (RFs), and DNA end-resection during DNA
double-strand break (DSB) repair. Each of these processes is important for genome stability,
and a key question we will address is which molecular role of Dna2DNA2 is essential for
cell survival and, by extension, perhaps the most likely explanation for its association with
human disease. Importantly, DNA2 has been identified as a candidate for targeted cancer
therapy [20,21]. We will discuss the relationship between Dna2DNA2′s essential role in cell
proliferation and a heightened susceptibility of cancer cells to DNA2 inhibition.
Int. J. Mol. Sci. 2021, 22, 3984. https://doi.org/10.3390/ijms22083984 https://www.mdpi.com/journal/ijms




Figure 1. Structure and function of Dna2DNA2. (a) Across organisms, Dna2DNA2 comprises a RecB nuclease and superfamily 
1 (SF1) helicase domain. The human (Hs) protein is 1060 amino acid residues in length, while budding yeast (Sc) Dna2 
spans 1522 amino acids with an additional N-terminal domain, which is unstructured and serves a redundant role in S 
phase checkpoint activation [22]. (b) A murine DNA2-ADP-ssDNA structure has been solved [23] showing that ssDNA 
substrates must thread through an internal channel containing the nuclease active site for cleavage (indicated by a scissors 
symbol). Exiting this channel, a 5′-ended strand may productively engage the SF1 helicase (represented through its sub-
domains 1A and 2A with the ATP-binding site indicated), which exhibits 5′-to-3′ translocation polarity (indicated by an 
arrow). In this arrangement, DNA cleavage will disrupt further translocation activity such that the actions of the nuclease 
domain effectively control the extent of ATPase/helicase activity. This is consistent with biochemical analyses, in which 
the full capacity of the helicase activity of Dna2DNA2 is only revealed when the nuclease is experimentally inactivated 
[24,25]. Dna2DNA2 can also degrade ssDNA from the 3′-end, but it is unclear whether the helicase domain has a role in this. 
How the actions of the nuclease and helicase domains are coordinated in vivo remains to be fully elucidated, but a close 
cooperation of their activities in all pathways involving Dna2DNA2 is highly likely. 
2. Discovery of Dna2DNA2 and Models for Its Essential Function in Cells 
Screening a collection of temperature sensitive S. cerevisiae mutants [26] for proteins 
involved in DNA replication, Campbell and co-workers identified mutant dna2-1 [1,2]. At 
the restrictive temperature, dna2-1 cells (bearing mutation P504S, which maps to the nu-
clease domain but was later shown to affect Dna2′s nuclease and helicase activities [27]) 
appeared to quickly cease DNA synthesis, suggesting that Dna2 might be an essential 
DNA replication factor in eukaryotes [1,2]. While it turned out that Dna2 is not required 
for DNA synthesis per se, it quickly became apparent that Dna2 is a key replication factor 
whose dysfunction during S phase of the cell cycle results in DNA damage checkpoint 
activation and cessation of cell proliferation [28]. To date, two models have been proposed 
to explain the essential function of Dna2 during DNA replication. According to model 1, 
Dna2 is indispensable for lagging strand replication, specifically for the removal of DNA 
flaps at maturing Okazaki fragments [29]. Model 2 suggests that Dna2 is essential for 
proper processing and recovery of stalled RFs [30]. These models, which are largely based 
on work in yeast, provide a framework to rationalize the most severe cellular and organ-
ismal phenotypes associated with DNA2 dysfunction. 
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2. Dis overy of Dna2DNA2 and Models for Its Ess ntial Function in Cells
Screening a collection of temperature sensitive S. cerevisiae mutants [26] for proteins
involved in DNA replication, Campbell and co-workers identified mutant dna2-1 [1,2].
At the restrictive temperature, dna2-1 cells (bearing mutation P504S, which maps to the
nuclease domain but was later show to affect Dna2′s nuclease and helicase activities [27])
appea d to quickly cease DNA s nthesis, suggesting that Dna2 might be an essential DNA
replication factor in eukaryotes [1,2]. While it turned out that Dna2 is not requ red for DNA
synthesis per se, it quickly becam apparent that Dna2 is a key replication fa tor whose
dysfunction uring S phase of the cell cycle results in DNA da ag c eckpoint activation
and cessation of c ll proliferation [28]. To ate, two mod ls h ve been proposed to explain
the essential fu ction of Dna2 during DNA replication. A cording to model 1, Dna2 is
indispensable for lagging st nd replication, sp cifically for the removal of DNA flaps
at maturing Okazaki f agm nts [29]. Model 2 suggest that Dna2 is essenti l for proper
processing and recovery of stall d RFs [30]. These models, which are largely based on
work in yeast, rovide a framework to rationalize the most severe cellular and organismal
phenotypes associated with DNA2 dysfunction.
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2.1. Model 1: Dna2DNA2 Plays an Essential Role during Okazaki Fragment Maturation
During DNA replication, the leading strand is synthesized in continuous fashion by
DNA polymerase (Pol) ε, while the lagging strand is discontinuously synthesized by Pol δ
in the form of 100–200 nucleotide (nt)-long fragments known as Okazaki fragments [31].
Each Okazaki fragment is initiated by the Pol α-primase complex, which lays down a
short primer composed of RNA and initiator DNA. When Pol δ encounters the 5′-end
of the preceding Okazaki fragment, this primer is dissociated from the lagging strand
template through strand-displacement DNA synthesis and removed with the help of 5′-
flap endonuclease Rad27 (FEN1 in human). Rapid nucleosome deposition on the nascent
sister chromatids behind moving RFs restricts this process, avoiding excessive strand-
displacement synthesis by Pol δ. Accordingly, most Okazaki fragments conform to the
nucleosomal repeat length of ~165 bp in S. cerevisiae [32]. Once Pol δ dissociates, DNA ligase
I fuses adjacent Okazaki fragments to form a mature lagging strand.
2.1.1. The Two-Nuclease OFP Model Involving Rad27FEN1 and Dna2DNA2
Dna2 was first implicated in OFP through guilt by association when co-immunopre-
cipitation experiments indicated a physical interaction with Rad27 [33]. Furthermore,
overexpression of Dna2 partially suppressed the lethality of rad27∆ cells at elevated temper-
atures, consistent with a degree of functional compensation. Biochemical studies with Dna2
revealed endonuclease activity on both 5′- and 3′-ended ssDNA, and while free ssDNA
ends proved to be the preferred substrate, limited duplex unwinding activity allowed
access and some nucleolytic processing at fully annealed DNA ends [18,19]. The presence
of ssDNA-binding protein RPA was then shown to stimulate the 5′-flap cleavage activity
of Dna2, while it inhibits Rad27 [19,34]. Together, these findings formed the basis for a
two-nuclease model for OFP based on cooperation between Dna2DNA2 and Rad27FEN1
in removing 5′-flaps [19,34,35]. Accordingly, Pol δ-dependent DNA strand displacement
during Okazaki fragment synthesis displaces 5′-flaps of sufficient length—i.e., greater than
~30 nt—for RPA to bind. This would both necessitate and stimulate processing by Dna2,
which would trim down long 5′-flaps to a size no longer able to support RPA binding,
and thus amenable to further processing by Rad27 [36]. Alternatively, Dna2 may fully re-
move 5′-flaps to allow immediate Okazaki fragment ligation [37] (Figure 2). Dna2′s ability
to deal with long, RPA-bound, and short 5′-flaps—as compared to Rad27′s limitation to
short flaps free of RPA—could explain why Rad27 is dispensable for cell viability in yeast
while Dna2 is strictly required.
Reconstituted OFP reactions, however, have not indicated a significant role for Dna2.
In these experiments, the actions of Pol δ and Rad27 are coordinated by the PCNA sliding
clamp (to which they both bind), and Rad27 exhibits such great efficiency in cleaving
nascent 5′-flaps, generated through strand-displacement synthesis, that flaps large enough
to attract RPA are unlikely to emerge [36,38,39]. Further in vitro studies have shown that
nascent 5′-flaps act like a molecular brake on Pol δ [40]. As a consequence, OFP proceeds
by iterative cycles of single-nt flap formation and instantaneous mini-flap removal by
Rad27 [31]. Long-flap formation necessitating intervention by Dna2 does not appear to be
an integral part of OFP.
2.1.2. Supporting Genetic Evidence for the Two-Nuclease OFP Model
While OFP reconstitution did not provide concrete evidence of a requirement for Dna2,
the identification of three suppressors of dna2∆ cell lethality in yeast provided fresh support
for an essential role of Dna2 in OFP in vivo. Accordingly, loss (or nuclear exclusion) of
the conserved helicase Pif1 [41], the Pol δ subunit Pol32 [41–44], and the DNA damage
checkpoint mediator Rad9 [28,45,46] (see also [47]) was shown to restore viability to dna2
mutants. These observations indicated that Pif1 and Pol32 drive the accumulation of DNA
damage checkpoint-activating DNA intermediates in the absence of Dna2, and that this
results in checkpoint-mediated growth inhibition and cell death. Biochemical studies
showed that Pif1 and Pol32 promote the processivity of Pol δ, potentially increasing strand
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displacement on the lagging strand in vivo. Reconstituted Okazaki fragment maturation
supported the notion that the presence of Pif1 might result in at least a small proportion of
long-flap intermediates [44,48] (Figure 2). In a fully reconstituted OFP reaction, however,
Dna2 still was not required for strand maturation, even in the presence of Pif1 and RPA.
On the other hand, Dna2 allowed the processing of substrates with pre-formed 30-nt 5′-
flaps bound with RPA [49]. Accordingly, Dna2 does provide a way for cells to deal with
any eventuality of excessive strand-displacement DNA synthesis during Okazaki fragment
maturation (reviewed in [50,51]).
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strand in a continuous fashion while Pol δ sy thesizes the lagging strand discontinuously in the form of Okazaki fragments.
Limited strand-displacement DNA synthesis by Pol δ and instantaneous cleavage by Rad27 ensures the RNA/initiator DNA
primer at the 5′-end of each Okazaki fragment is removed through nick translation (iterative cycles of ~1 nt-flap generation
and removal). DNA ligase I seals the final nick to establish the continuity of the lagging strand. The Pol32 subunit of Pol
δ and the actions of the Pif1 helicase stimulate the strand-displacement activity of Pol δ, potentially leading to 5′-flaps
> ~30 nt, which become refractory to Rad27 by association with ssDNA-binding protein RPA. This creates an essential
requirement for Dna2, which, unlike Rad27, is able to cleave RPA-covered flaps. In the absence of Dna2, RPA-covered flaps
may accumulate and activate the DNA damage checkpoint in a Rad9-dependent manner, leading to a persistent cell-cycle
arrest and, ultimately, cell de th.
Why cells might have evolved a Pif1-dependent mechanism for long-flap formation
at Okazaki fragments, and whether long flaps occur in vivo, remained unclear. Since Pol
α lacks proofreading ability, a mechanism for enhanced strand displacement could help
sanitize base substitution errors introduced by Pol α on the lagging strand [52]. However,
mutation rates of pol32∆ and pif1∆ strains are very similar to wild type [53], indicating that
enhanced strand displacement mediated by Pif1 and Pol32 may not be a requirement for
effective removal of Pol α errors from Okazaki fragments. Regardless, considering the sheer
number of Okazaki fragments produced in every cell cycle, it is conceivable that the absence
of Dna2 might lead to a build-up of RPA-bound 5′-flaps, even if nascent flaps very rarely
escape instantaneous Rad27 cleavage, and despite the weak strand-displacement synthesis
activity of Pol δ in the face of nascent flaps. RPA-ssDNA is a potent activator of checkpoint
kinase Mec1 (ATR in human) [54], and elicits a DNA damage checkpoint response in a
dose-dependent manner [55,56]. An accumulation of RPA-ssDNA on the lagging strand
could therefore ultimately provoke the lethal event in dna2∆ cells: hyperactivation of the
DNA damage checkpoint leading to terminal cell-cycle arrest at the G2/M boundary in a
Mec1ATR and Rad9 (53BP1 in human)-dependent manner [29,46] (Figure 2).
2.1.3. Limited In Vivo Evidence for an Essential Role of Dna2 in OFP
The use of electron microscopy (EM) has provided some evidence for an accumu-
lation of DNA-flap structures upon loss of Dna2 activity. One study used germinating
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Schizosaccharomyces pombe spores [57], which have the capacity to divide several times be-
fore cell-cycle progression is blocked when Dna2 is absent [58]. In the wild type, DNA flaps
in the range of ~50 nt were observed near RFs; these structures were more frequent and
grew to ~100 to 150 nt when Rad2, the fission yeast Rad27FEN1 homolog, and/or Dna2 were
absent [57]. This phenotypic similarity between rad2- and dna2- cells is perhaps surprising,
given that Rad2FEN1 is believed to process the lion’s share of Okazaki fragment-associated
DNA flaps, and that any contribution of Dna2 is likely to be very limited. It remains to be
determined whether the DNA flaps observed in dna2- germinating spores are dependent on
Pif1, which would make them more likely candidates for the toxic intermediates that lead
to dna2- inviability. Another EM study has identified a range of DNA intermediates that
accumulate in replicating budding yeast cells upon acute depletion of Dna2 [59]. The bulk
of these structures consisted of double-stranded DNA (dsDNA) molecules with an ex-
tended branch of ssDNA with a mean length of ~3000 nt. The potential for extensive RPA
binding and the dependence of these structures on Pif1 is consistent with the notion that
these unusual intermediates represent the origin of checkpoint activation that restricts the
viability of dna2∆ cells [59]. On the other hand, rapid nucleosome deposition on nascent
sister chromatids is known to block any extended strand-displacement DNA synthesis by
Pol δ, making it unlikely that such long tracts of ssDNA are generated by lagging-strand
replication [32,60]. This raises the possibility that Pif1-dependent ssDNA accumulation
in the absence of Dna2 results from a process other than Okazaki fragment maturation,
potentially inadequate RF recovery (as discussed in detail below in Section 2.2).
In human cells, depletion of DNA2 had no measurable effect on the maturation
kinetics of Okazaki fragments [16]. This is in contrast to depletion of DNA ligase I or FEN1,
which resulted in unligated nascent DNA, indicating failed Okazaki fragment maturation.
Importantly, co-depletion of FEN1 and DNA2 did not exacerbate the maturation defect
detected upon single depletion of FEN1 [16]. These findings are incongruent with a
conserved role of Dna2DNA2 in preserving cell viability in absence of Rad27FEN1 through
functional compensation during OFP [16]. More recently, careful analysis of lagging-strand
replication by Okazaki-fragment sequencing in yeast showed that the loss of Okazaki
fragment maturation nucleases Rad27 and Exo1, but not Dna2, resulted in reduced—rather
than excessive—stand-displacement synthesis by Pol δ [61]. This is in keeping with the
above-mentioned inhibition of Pol δ-dependent nucleotide incorporation by nascent 5′-
flaps, which restricts flaps at Okazaki fragment junctions to a length of one or a few
nucleotides [40,62]. Furthermore, Dna2 did not affect the position of Okazaki fragment
termini, even in the absence of Rad27 and Exo1, indicating Dna2 is dispensable for OFP
in vivo [61]. Okazaki-fragment sequencing further revealed that while Pif1 stimulates
Pol δ progression in vivo, it does so redundantly with Rrm3, a related helicase present in
budding yeast [63]. As a consequence, loss of Pif1 did not lead to detectable changes in
strand-displacement DNA synthesis. Since reduced strand displacement in absence of Pif1
is the proposed mechanism suppressing dna2∆ lethality, this raises serious doubts whether
Pif1-mediated toxicity in dna2∆ can be explained on the basis of long-flap formation
during OFP [63].
In conclusion, Dna2 has the ability to cleave RPA-covered DNA flaps that are refractory
to Rad27, supporting the model of an essential role of DNA2 in policing long-flap formation
during Okazaki fragment maturation (Figure 2). Reconstitution of lagging strand DNA
synthesis suggests that the strand-displacement activity of Pol δ is limited, and that the
odds are greatly stacked against long-flap formation. This resonates with Okazaki fragment
sequencing results, which have failed to detect a requirement for Dna2 during OFP in vivo.
A minor involvement of Dna2 in Okazaki fragment maturation in vivo is a likely possibility,
but other molecular processes must be considered to explain the essential contribution of
DNA2 to cell viability.
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2.2. Model 2: DNA2 Plays an Essential Role in the Processing and Recovery of Stalled RFs
DNA replication relies on the unfettered activity of RFs, which must track the entire
length of every chromosome to synthesize a complete copy of the genome in every cell
cycle. Along the way, RF movement can be impaired by DNA damage, ongoing transcrip-
tion, template-bound proteins, DNA secondary structures, and imbalances in replication
factors or deoxyribonucleotide triphosphate (dNTP) pools, which results in replication
stress [64]. When RFs stall, they undergo controlled nucleolytic processing and structural
rearrangements to promote RF recovery. A prominent pathway involves dissociation of
the nascent leading and lagging strands, which may subsequently anneal with one another
to convert a three-way RF into a four-way Holliday junction-like structure known as a
“chicken-foot” intermediate (see Figure 3). Such reversed RFs have been directly visualized
in a range of organisms from yeast to human by EM [65]. RF architectural rearrangements
are thought to provide a platform for stable RF pausing, RF reactivation, and homologous
recombination-mediated replication restart [66]. Normally transient, stalled and reversed
RFs have been shown to accumulate upon loss or depletion of Dna2DNA2, implicating the
protein in the processing of stalled RF intermediates [59,67,68].
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dissociated single-strands and fully reversed RFs. Controlled nascent-strand degradation by Dna2 restores a canonical
three-way RF architecture and promotes replication completion. Intermediates escaping the attention of Dna2 physically
link sister chromatids at sites of underreplication and preclude chromoso e segregation. Holliday junction resolvase Yen1
provides a fail-safe m chanism for the removal of persistent replication intermediates in mitosis. The interplay between
DNA2 and the human Yen1-homolog GEN1 remains to be investigated. DNA intermediates colored red are non-productive
in DNA replication and their processing ( reen arrows) is required for complete chromosome replication and proper
chromosome segregation.
2.2.1. The Dna2 Nuclease and Helicase Activities Promote the Recovery of Stalled RFs
An early indication for the involvement of Dna2 in RF recovery came from dna2
alleles in budding yeast bearing mutations in the Dna2 helicase domain [45]. In contrast
to the nuclease activity, the helicase activity turned out to be non-essential, but Dna2
helicase mutants exhibited sensitivity to DNA base damage, dNTP s ortage, and genetic
perturbation of the replication machinery. Accordingly, h licase-def ctive dna2 cells showed
sensitivity to alkylating agent meth l methanesulfonate and did not tolerate the loss
of Ctf4 (AND-1 in human), an i tegral but non-esse tial component of the replication
mac inery [45]. Simil rly, mutations in the Dna2 helicase domain sensitized cells to the
ribonucleotide reductase inhibitor hydroxyurea (lowering dNTP availability) and mutation
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of another replication factor, Mcm10 [69,70]. These observations of replication stress
sensitivity led to the suggestion that Dna2 may be required to overcome RF pausing or
participate in the repair of stalled RFs [69]. Since then, a growing list of negative genetic
interactions with factors that play critical roles in maintaining the stability of stalled RFs
has solidified this notion [43,71]. For example, the most severe negative interactors of
helicase-dead allele dna2-2 were found to include all components of the Mrc1-Csm3-Tof1
(Claspin-Timeless-Tipin in human) fork protection and the Rtt101-Mms1-Mms22 (CUL4-
DDB1-MMS22L) fork repair complexes [71].
The first mechanistic insights into how Dna2 might act to facilitate RF recovery came
from a study in fission yeast [67]. Dna2 was identified as a binder of chromatin and
model RFs when isolated from cells exposed to replication stress. These associations were
dependent upon phosphorylation of Dna2 amino acid residue S220, mediated by the S
phase checkpoint kinase Cds1 (analogous to Rad53 in budding yeast and CHK1 in human).
Loss of Cds1, mutation of the S220 phosphorylation site within Dna2, or inactivation of
Dna2 led to an accumulation of reversed RFs detected by EM, in particular upon exposure
of cells to replication stress [67]. This was reminiscent of budding yeast, where Rad53
had been show to protect stalled RFs and suppress the accumulation of chicken-foot
structures to levels detectable by EM [72,73], and suggested that the checkpoint acts
through Dna2 to promote RF recovery. Notably, acute depletion of Dna2 in budding yeast
was recently shown to result in an accumulation of aberrant replication intermediates,
including chicken-foot structures [59]. In vitro, fission yeast Dna2 was shown to remove
3′-and 5′-ssDNA from DNA three-way junctions mimicking reversed RFs with dissociated
leading and lagging strands attached to them [67]. Based on their results, Hu and co-
workers proposed the following model: replication stress results in S phase checkpoint-
dependent Dna2 phosphorylation and recruitment to stalled RFs. The Dna2 nuclease then
degrades any dissociating nascent DNA, essentially counteracting the formation of chicken-
foot structures to promote RF stability and recovery (Figure 3). The study did not find a role
for Dna2′s helicase activity, but the requirement for the Dna2 helicase activity at stalled RFs
was subsequently demonstrated in budding yeast [74,75]. Replication stress-sensitive Dna2
variant R1253Q (encoded by the dna2-2 allele [45]) was shown to be ATPase/helicase-dead,
while retaining wild-type nuclease activity on RPA-covered DNA flaps [74]. Loss of only
Dna2′s helicase activity rendered cells unable to fully complete chromosome replication,
resulting in anaphase bridge-like structures between segregating chromosomes at mitosis.
Viable chromosome segregation became dependent on Holliday junction resolvase Yen1
(GEN1 in human) [76–78], a structure-specific nuclease that is activated upon anaphase
entry [79,80]. These findings showed that the Dna2 helicase activity contributes to the
processing of at least a subset of stalled replication intermediates to ensure DNA replication
is faithfully completed before mitosis [74,81]. The helicase activity of Dna2 has been shown
to promote ssDNA degradation by the Dna2 nuclease during DSB end-resection [25,82]
(see Section 2.3.1), and to facilitate access to, and cleavage of, DNA flaps containing
DNA secondary structures [83]. A similar cooperation of the Dna2 helicase and nuclease
domains could increase the effectiveness of nascent ssDNA removal from stalled RFs. In an
alternative, but not mutually exclusive, scenario, Dna2 may rely on its helicase activity
upon chicken-foot formation to dissociate the annealing leading and lagging strands,
providing the nuclease domain access for ssDNA degradation. Regardless of the exact
mechanism of action, these observations are consistent with coordinated actions of the
Dna2 nuclease and helicase activities, at stalled RFs, to maintain or restore fork architectures
conducive to replication completion, either by allowing RF restart and/or fusion with an
oncoming fork. Occasional replication structures escaping the attention of Dna2 may persist
into mitosis and jeopardize proper chromosome segregation, but these can be resolved
nucleolytically by Yen1 (Figure 3).
Similar to what has been observed in yeast, human DNA2 appears to be dispens-
able for bulk DNA synthesis in S phase but required to fully complete chromosome
replication. Accordingly, DNA2 depletion in human cells has been shown to lead to chro-
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mosome bridges and micronuclei formation at mitosis [16]. More recently, DNA fiber
analysis, which allows monitoring replication arrest and restart on the single-molecule
level, showed that human DNA2 promotes RF recovery after transient exposure of cells
to replication stress induced by hydroxyurea [68] (see Section 3.1). Thus, in contrast to a
proposed role in OFP, there is clear evidence that the role of Dna2DNA2 in RF recovery is
conserved from yeast to human.
2.2.2. Evidence Supporting That Dna2′s Role in RF Recovery Is Essential for Cell Viability
A conserved role of Dna2DNA2 in counteracting RF reversal, anaphase-bridge for-
mation, mitotic failure, and replication stress sensitivity raises the question whether RF
recovery can account for the essential requirement of Dna2 for cell viability. As mentioned
above, in budding yeast, cell death in absence of Dna2 is driven by a Pif1/Pol32-dependent
process, which ultimately gives rise to DNA structures that activate a Rad9-dependent
checkpoint response, cell-cycle arrest and cell death. Accordingly, deletion/inactivation of
PIF1, POL32, or RAD9 suppresses dna2∆ lethality [28,41–47]. However, not even the most
potent suppressor mutations, those in PIF1, restore resistance to exogenous replication
stress in dna2∆ cells [41,84]. This may suggest that the response of Dna2 to stalled RFs
and the toxicity generated along the Pif1/Pol32/Rad9 pathway in unperturbed conditions
are separate issues. Conceivably, Pif1/Pol32/Rad9-driven toxicity in dna2∆ cells may
relate to faulty OFP, and severe replication-stress sensitivity in dna2∆ pif1 double-mutant
cells to perturbed RF recovery. In other words, both pathways could in principle make
independent contributions to loss of viability in absence of Dna2. However, recent findings
indicating that, in dna2∆ cells, Pif1-dependent toxicity arises at unresolved RFs as a result
of excessive recombination-dependent replication (RDR) restart, suggest otherwise [84].
This link between failed RF recovery in dna2∆ cells and Pif1-driven cell death, as explained
in more detail below, indicates that Dna2-dependent RF recovery represents not only an
important function in promoting replication completion, but also the sought-after essential
function provided by Dna2 to ensure cell survival [30,84].
In budding yeast, dna2∆ cells that survive on account of the disruption or nuclear
exclusion of Pif1 exhibit a chromosome-underreplication phenotype that manifests itself
in the form of post-replicative chromosome entanglements [84]. In unperturbed condi-
tions, this phenotype was most prominent for chromosome XII containing the difficult-to-
replicate rDNA array, and dna2∆ pif1 double mutants required Yen1 to maintain viability.
Following transient RF arrest induced by hydroxyurea, chromosome underreplication was
exacerbated and extended genome-wide. Collectively, these results demonstrate that loss of
Dna2 compromises proper RF recovery and replication completion, and that these defects
are independent of Pif1 [84]. To test the effect of Pif1, Dna2 helicase-dead cells were used.
These cells are compromised in RF recovery and replication completion, but less so than
dna2∆ cells; while they are affected by Pif1-mediated toxicity, they can be grown in the
presence of Pif1 [74,84]. When these Dna2 hypomorphic cells were transiently exposed to
replication stress, post-replicative DNA damage checkpoint activation and cell-cycle arrest
at the G2/M transition ensued in a strictly Pif1/Rad9-dependent manner [74,84]. This is
consistent with inappropriate actions of Pif1 at perturbed replication intermediates that
would normally be handled by Dna2.
An important insight into Pif1-mediated toxicity came from the realization that Pif1-
driven checkpoint activation in dna2 cells correlates with Pif1′s ability to support homol-
ogous recombination-dependent DNA synthesis [84–87], a mechanism that can be used
to restart stalled or broken RFs [88]. At a broken RF, the ensuing single-ended DSB is
resected to expose a 3′-overhang that serves as a strand-invasion substrate for recombinase
Rad51. Strand invasion into the intact sister chromatid generates a displacement loop
(D-loop), which becomes the site of DNA synthesis in a pathway known as break-induced
replication (BIR) [89]. At stalled RFs, fork reversal into a chicken-foot structure provides
a recombinogenic, DSB-like substrate at the tip of the regression arm. Following 5′-end
resection, Rad51 mediates strand invasion ahead of the backtracked RF to restart DNA
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synthesis by RDR. D-loop progression during BIR/RDR is strictly dependent on Pif1
(and Pol32) [90–94]. DNA synthesis in the context of a D-loop can proceed over long
distances, but D-loop collapse is frequent, resulting in the exposure of long tracts of newly
synthesized ssDNA [95–99]. Accordingly, excessive use of RDR in lieu of RF recovery by
Dna2 could create a situation where toxic levels of ssDNA are generated through D-loop
collapse, providing a plausible explanation for Rad9-dependent checkpoint activation
and terminal cell-cycle arrest in Dna2-mutant cells [30,84] (Figure 4). In contrast to OFP,
where nascent nucleosomes and flap formation restrict any extended strand-displacement
DNA synthesis by Pol δ [32,40,60,62], RDR DNA-synthesis tracts can be thousands of
nucleotides in length. A model of excessive RDR and D-loop collapse would therefore
predict the accumulation of heterogeneously sized ssDNA tracts of extensive length rather
than small flaps in dna2∆ cells. Interestingly, Pif1-dependent intermediates consisting of
dsDNA with ssDNA branches of a few hundred to more than 10,000 nt have been observed
in budding yeast upon depletion of Dna2 [59]. In future, it will be important to address
directly the ability of Dna2 to limit RDR at a defined locus of RF arrest.
In conclusion, Dna2′s RF recovery role is of fundamental importance for the com-
pletion of DNA replication and to prevent the excessive use of alternative fork restart
pathways. Considering the increased complexity of the human genome, a similarly es-
sential requirement of human DNA2 on account of its RF recovery function seems likely
(discussed in Section 3 below).
2.3. Other Functions of DNA2
In addition to OFP and RF recovery, DNA2 has been implicated in DSB end-resection
and the maintenance of telomeric, centromeric, and mitochondrial DNA (mtDNA) across
organisms. The yeast-specific N-terminal domain of Dna2, which is not conserved in higher
eukaryotes, serves a non-essential role in S phase checkpoint activation through physical
interaction with Mec1ATR [22]; for a discussion of this checkpoint stimulatory function,
please see [100]. For the purpose of this review, we will briefly describe Dna2′s end-
resection activity, as well as its telomeric/centromeric and mitochondrial roles, which could
entail specialized Dna2 activities, or reflect the ability of Dna2 to promote the progression
of RFs through difficult-to-replicate regions of the genome.
2.3.1. DSB End-Resection
Several nucleases mediate end-resection at chromosomal DSBs, and Dna2DNA2 has
been shown to be one of them [101,102]. End-resection is a prerequisite for the faithful
repair of DSBs by homologous recombination-dependent mechanisms [103]. To initiate
recombinational repair, DSBs must be resected at the 5′-terminated strand, which results in
3′-ssDNA overhangs that constitute the substrate for the central recombinase Rad51RAD51.
Polymerization of Rad51RAD51 on the 3′-overhangs generates nucleoprotein filaments
capable of seeking out and invading a DSB repair template of homologous DNA sequence.
Repair DNA synthesis and the resolution of recombination intermediates then restores the
damaged sequence at the break site [103].
DSB end-resection can be divided in two phases including short-range resection
dependent on the Mre11-Rad50-Xrs2 (MRE11-RAD50-NBS1 in human) complex and
Sae2CtIP, followed by long-range resection mediated redundantly along pathways defined
by Exo1EXO1 and Sgs1 (Bloom syndrome helicase BLM in human)-Dna2DNA2 [102,104–106].
In contrast to Exo1EXO1, which degrades DNA exonucleolytically, Dna2DNA2, due to its
anatomy, prefers substrates with overhanging ssDNA that can feed into the tunnel-like
structure containing the nuclease active site [23] (see Figure 1). The functional integra-
tion of Dna2DNA2 with Sgs1BLM ensures processive duplex unwinding, which generates
these ssDNA overhangs. RPA directs the nucleolytic activity of Dna2DNA2 towards the 5′-
terminated strands [101,107–109]. In human, Werner syndrome helicase WRN can take the
place of BLM and collaborate with DNA2 in DSB end-resection [24,110]. The helicase activ-
ity of Dna2DNA2 plays an accessory role and increases the speed and 5′-strand degradation
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specificity, during DSB end-resection [25,82]. In the absence of Dna2, Exo1 still provides
significant end-resection capacity in budding yeast. Consistent with this, disruption of
Dna2-dependent end-resection by deletion of SGS1 does not result in cell lethality [106].
Thus, while the DSB end-resection function of Dna2DNA2 is conserved, the essential role of
DNA2 for cell survival lies elsewhere.
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suppresses the lethality of dna2∆ cells. Red DNA strands denote non-productive intermediates.
Int. J. Mol. Sci. 2021, 22, 3984 11 of 24
2.3.2. Dna2DNA2 and the Maintenance of Telomeric, Centromeric, and mtDNA
Dna2DNA2 has been observed at telomeres in yeast and mouse embryonic fibrob-
lasts [8,111]. In budding yeast, loss of Dna2′s helicase activity resulted in abnormal telomere
length, indicative of perturbed telomere replication [45,111]. Similarly, DNA2 haploinsuffi-
ciency in mouse cells resulted in telomere fragility and loss [8]. Telomere fragility can arise
under replication stress conditions as a consequence of incomplete replication [112–114].
In DNA2-deficient cells, this phenotype was aggravated in the presence of G-quadruplex
DNA (G4)-stabilizing drugs, consistent with a requirement for DNA2 to replicate through
DNA secondary structures formed at TTAGGG repeats found within telomeric DNA.
This has been suggested to reflect the ability of DNA2 to cleave and remove G4 structures,
thereby facilitating RF progression across TTAGGG repeats [8]. Yeast and mouse Dna2DNA2
have been shown to cut G4 DNA with a proximal ssDNA tail, for example within a 5′-flap
intermediate [8,115]. The mammalian enzyme was much less effective in cleaving G4s in
a bubble structure delimited by dsDNA on either side, and unable to cleave substrates
mimicking G4 formation within the lagging strand template [8]. These observations are
consistent with the structure of mouse DNA2 showing the need of threading a ssDNA
end into the tunnel containing the nuclease active site for cleavage [23] (see Figure 1).
Accordingly, the ability of DNA2 to directly remove G4s in the parental DNA to promote
RF progression in this way is limited. This raises the possibility that replication stress
induced by G4 DNA (and potentially by other telomeric features including RNA:DNA
hybrids involving telomeric repeat-containing RNA [116]) could be resolved by DNA2 in
its capacity as a RF recovery factor. Hence, DNA2 may process replication intermediates
to counteract the reversal of RFs stalled at G4 structures and other telomeric obstacles to
promote restart and the completion of telomere replication. In other words, loss of the
role of Dna2DNA2 in RF recovery described above may manifest itself most prominently in
difficult-to-replicate areas, such as, for example, telomeric DNA in mouse cells [8], or the
rDNA in budding yeast [84]. This resonates with findings of incomplete replication of
centromeric regions in human cells upon loss of DNA2 [117]. Cre-mediated excision of
DNA2 in cycling human cells led to shortened replication tracks in centromeric DNA;
restoration of normal track length required both the helicase and nuclease activity of
DNA2 [117]. Like telomeres, centromeres contain repetitive DNA sequences and pose a
particular challenge to the progression of RFs. DNA2 could be needed to remove obstacles
arising at centromeres, for example DNA secondary structures, or to ensure recovery of RFs
stalled along the centromeric regions of chromosomes. Overall, the exquisite sensitivity of
the rDNA, telomeres, and centromeric regions supports the conjecture that counteracting
RF arrest and the associated risk of chromosome underreplication is the critical role of
Dna2DNA2 in ensuring cell viability.
While Dna2DNA2 mediates chromosome replication in the nucleus, the protein has also
been implicated in mtDNA replication [41,118,119]. Its precise function in mitochondria is
among the least-well understood aspects of Dna2DNA2 biology, in part because the mode
of mtDNA replication has not been fully elucidated [120]. Interestingly, human DNA2
was shown to accumulate on mtDNA under conditions of replication stalling induced by
mutations within the mitochondrial replicative helicase Twinkle [119]. This may suggest
a similar role of Dna2DNA2 in the recovery of stalled RF intermediates in the nucleus
and mitochondria.
3. An Essential Role of Human DNA2 in RF Recovery?
As described in Section 2, yeast Dna2 has been implicated in DSB end-resection,
OFP, and RF recovery. The latter two pathways have each been proposed to account for
the essential requirement for DNA2 [29,30]. Precise measurements of Okazaki fragment
maturation in vitro, and recent Okazaki fragment sequencing results in particular, have in-
dicated that the contribution of Dna2 to OFP could be much less significant than previously
assumed [40,61]. Experiments in human cells have failed to detect a role for DNA2 in OFP.
Duxin and co-workers showed that following replication, nascent DNA did not contain
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excess unligated Okazaki fragments upon depletion of DNA2, unlike in the absence of
FEN1, which led to the suggestion that DNA2 may not be involved in OFP in human [16].
In contrast to OFP, Dna2DNA2
′
s role in RF recovery is conserved from yeast to human and
chromosomes remain incompletely replicated when Dna2DNA2 is absent or depleted across
organisms [8,16,84,117,119].
3.1. RF Restart Mediated by Human DNA2
Similar to findings in yeast, human cells depleted for DNA2 are inefficient at restart-
ing stalled RFs. Accordingly, DNA2 depletion results in sensitivity to DNA-damaging
agents and dNTP depletion by hydroxyurea, i.e., conditions that impede RF progres-
sion [16,17]. DNA2 is also required to survive replication stress associated with oncogene
expression [21] (discussed in Section 4.2.1). DNA fiber analysis showed, at the level of
individual forks, that DNA2 aids efficient RF restart following treatment of cells with
hydroxyurea, the topoisomerase poison camptothecin, or the DNA crosslinking-agent
mitomycin C. In this pathway of RF recovery, DNA2 was found to act epistatically with
the WRN helicase [68]. Although WRN and BLM have both been shown to function with
DNA2 in end-resection at DSBs (see Section 2.3.1), in fork restart BLM cannot compensate
for the loss of WRN, potentially reflecting the presence of differing protein complexes or
DNA target structures at these distinct repair sites.
DNA2 supports human cell survival not only under conditions of exogenous repli-
cation stress, but also in unperturbed growth. The defects observed following DNA2
depletion appear to be caused by a problem in completing DNA replication, suggest-
ing that the role of DNA2 in restarting stalled RFs may be essential under normal growth
conditions [16,17,117,119]. Thus, reminiscent of the situation in yeast [74,84], cells traversed
S phase and achieved bulk replication following depletion of DNA2, but accumulated in
G2 phase and mitosis with associated chromosome shattering, aneuploidy, micronuclei for-
mation, and internuclei DNA bridges. Normal cell proliferation required both the nuclease
and helicase activity of DNA2 [16,17].
At RF level, depletion of DNA2 was shown to result in an accumulation of chicken-foot
structures by EM, both during unperturbed growth and under conditions of exogenous
replication stress. This phenotype was aggravated upon co-depletion of the helicase
RECQ1 [68]. RECQ1 can mediate DNA branch migration, essentially moving the junc-
tion point of a chicken-foot intermediate to the tip of the regressed arm that is formed
by the nascent leading and lagging strands upon RF reversal. In the wake of the mi-
grating junction point, the unwound nascent strands reanneal to the parental template,
which leads to restoration of a canonical three-way RF structure by this non-nucleolytic
conversion [121]. DNA2 therefore appears to act in a parallel pathway to RECQ1-mediated
branch migration to counteract RF reversal and promote stalled RF recovery in human
cells [68]. In unperturbed conditions, DNA2 depletion results in relatively high levels
of reversed RFs [68] and post-replicative chromosomal links at mitosis [16]. Together,
these observations suggest that DNA2′s role in RF recovery is indispensable for unper-
turbed replication and directly linked to the most severe cellular phenotypes that have
been observed in its absence. Consistent with this notion is the apparent vulnerability of
difficult-to-replicate regions of the genome to loss of DNA2. As discussed in Section 2.3.2,
DNA2 is needed to properly replicate the centromeric and telomeric DNA in mammalian
cells [8,117]. Human DNA2 is enriched at centromeric DNA, and both its helicase and
nuclease activity were required for unfettered RF progression and normal deposition of
histone variant CENP-A at the centromere. Without DNA2, centromeric replication was
associated with replication stress, as evidenced by local activation of the apical checkpoint
kinase ATR [117], a potential consequence of loss of centromeric structural integrity [122].
Telomeric DNA is another endogenous source of enhanced RF stalling due to its repetitive
DNA sequence, transcriptional activity, and unidirectional mode of replication. In mouse
cells, DNA2 haploinsufficiency was accompanied by telomere fragility and loss, consis-
tent with elevated levels of replication stress [8]. Interestingly, an involvement of DNA2
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in ameliorating telomere-specific replication stress echoes with observations in cancer
cells that use a recombination-based mechanism, alternative lengthening of telomeres
(ALT), for telomere maintenance in lieu of telomerase reactivation. Accordingly, ALT was
increased after depletion of DNA2 [123]. Since ALT is thought to be initiated by replication
stress at telomeres [124], this indicates that loss of DNA2 exacerbates replication stress at
telomeres [123]. In unchallenged conditions, the difficult-to-replicate regions of the genome
may confer the essential requirement for Dna2DNA2 for cell survival.
How does human DNA2 act on stalled RFs? In Section 2.2.1, we have described
evidence from studies in yeast suggesting that the Dna2 nuclease and helicase activities
cooperate in the processing of stalled RFs to counteract RF reversal. It has been proposed
that Dna2 degrades any dissociating nascent DNA, thereby preempting chicken-foot for-
mation [67], and the same may apply to human DNA2. Alternatively, DNA2 could attack a
fully-fledged chicken-foot structure after the dissociated leading and lagging strands have
annealed with one another. The tip of the regressed arm generated in this way resembles a
DSB-end and DNA2 could act on it alone (see Figures 1 and 3) or, as in DSB end-resection
(see Section 2.3.1), with a supporting helicase that mediates duplex unwinding. The latter
possibility is supported by the finding that DNA2 and WRN are both required for the effi-
cient resumption of DNA synthesis after hydroxyurea-induced RF stalling [68]. It has been
proposed that DNA2 and WRN collaborate in the controlled unwinding and degradation
of the regressed arm at reversed RFs, and that this restores a three-way configuration that
allows DNA synthesis to resume [66,68].
While the precise actions of Dna2DNA2 at stalled RFs remain to be determined, it is clear
that, in its absence, replication intermediates remain unresolved, and genome duplication
incomplete, in both yeast and human cells. The literature to date is consistent with the
conjecture that the essential role of human DNA2 is intimately linked to the recovery of
stalled RFs, reflecting what has been suggested in yeast [84]. Whether, as proposed in yeast,
there is an additional risk of alternative RF restart by unscheduled RDR or other pathways
associated with checkpoint activation and cell-cycle arrest remains to be addressed in
human cells [30,84].
3.2. Controlled RF Processing and Recovery by DNA2 vs. Hyperresection of Unprotected Forks
In addition to its role in the controlled processing and recovery of stalled RFs, hu-
man DNA2 has been implicated in the extensive degradation of nascent DNA under certain
conditions. When fork progression is blocked over long periods of time by incubating cells
in the presence of hydroxyurea for several hours, DNA2 can degrade long stretches of
newly synthesized DNA equivalent to several kilobases at stalled RFs [68,125]. Using DNA
fiber analysis, it has been shown that this reaction requires the nuclease activity of DNA2
and the helicase activity of WRN, while the DNA2 helicase activity was dispensable [68].
This is in contrast to Dna2DNA2
′
s RF recovery function, which does depend on its nuclease
and helicase activities [16,74,117].
DNA2-dependent hyperresection has also been observed at de-protected stalled RFs
in cells missing one of a group of proteins that have been shown to control nuclease access
at stalled replication intermediates. Accordingly, DNA2 has been shown to drive excessive
nascent-strand degradation in the absence of BRCA2, RIF1, BOD1L, FANCD2, ABRO1,
and 53BP1 [126–132]. The pathological nature of stalled RF hyperresection is exemplified
in a study showing that depletion of DNA2 suppresses the sensitivity of cells lacking
fork-protection factor FANCD2 to replication-blocking DNA cross-linking agents [126].
Other end-resection nucleases catalyze similar reactions at de-protected RFs but appear
to be more selective. For example, MRE11 and EXO1 degrade stalled RFs in the absence
of BRCA2, yet, not upon loss of ABRO1 [128,133]. The basis for the versatility of DNA2,
and its ability to degrade persistently stalled RFs in the presence of the full fork-protection
machinery, in contrast to MRE11 and EXO1 [68], is currently unclear. The substrate for
DNA2-dependent hyperresection appears to be the chicken-foot structure. The formation
of chicken-foot intermediates at stalled RFs in human cells is a complex and active process
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that requires a host of factors such as RAD51 (in a recombination-independent role) and
the SNF2-family fork-remodeling enzymes SMARCAL1, HLTF, and ZRANB3 [134]. If any
of these factors are missing, RF reversal and uncontrolled hyperresection of stalled forks
by DNA2 is suppressed [68,132].
Importantly, while fork hyperresection arises from the engagement of DNA2 with
stalled replication intermediates, it is not a direct reflection of its RF recovery function.
If this were the case, DNA2 depletion should attenuate activation of the S phase checkpoint
kinase CHK1, which requires the generation of ssDNA. While such an attenuation has
been observed upon depletion of DNA2, this only occurs after prolonged replication stress,
probably because persistently stalled RFs disintegrate into DSBs, and DSB processing is
slowed in the absence of DNA2′s end-resection activity (see Section 2.3.1). Under more
physiological conditions, CHK1 signaling is elevated upon depletion or loss of DNA2,
consistent with the notion that DNA2 offsets replication stress and checkpoint signaling at
stalled RFs [16,117]. Moreover, transient replication stress does not lead to the type of fork
hyperresection seen after prolonged fork stalling. However, transient replication stress is
sufficient to create a requirement for DNA2 to mediate RF recovery [68]. This suggests that
nascent-strand degradation by DNA2 at stalled RFs under physiological conditions does
not extend over kilobases. Rather, controlled and limited fork processing by DNA2 is the
pathway to RF recovery and replication completion.
4. Links between DNA2′s Critical Role in DNA Replication and Human Disease
DNA2 mutations have been implicated in genetic diseases. Germline mutations in one
allele of DNA2 are associated with mitochondrial myopathy, while biallelic mutations give
rise to Seckel syndrome. In addition, DNA2 over-expression has been observed in cancer
and the protein is emerging as a potential target for anti-cancer therapy.
4.1. DNA2 in Human Genetic Diseases
4.1.1. Mitochondrial Myopathy
Adult-onset mitochondrial myopathy is a genetic disease characterized by mtDNA in-
stability and a progressive decline in muscle strength. Heterozygous missense mutations in
DNA2 have been identified in previously genetically uncharacterized patients, supporting a
proposed role of DNA2 in maintaining the mitochondrial genome (see Section 2.3.2). Mus-
cle tissue from each patient showed a range of mtDNA deletions [12]. Heterozygous DNA2
truncating mutations have been linked to an early onset of myopathy, observed in patients
younger than two years [14,135,136]. It currently is not clear whether these mutations result
in truncated versions of the protein, or whether transcripts are degraded by nonsense-
mediated decay leading to complete loss of the protein. Accordingly, DNA2 haploinsuf-
ficiency or deleterious actions of truncated versions of DNA2 could contribute to early
disease onset. The identified missense mutations map to the helicase and nuclease domains,
pointing to the importance of both enzymatic activities of DNA2 at normal capacity for
mtDNA maintenance (Figure 5). Purified mutant proteins with single point mutations
showed reduced nuclease and helicase activities, and, in one case, reduced nuclease but
enhanced helicase activity [12]. Based on other in vitro experiments, it has been suggested
that DNA2 may stimulate replication progression and/or RNA primer and DNA-flap
removal during replication and the repair of oxidative damage in mitochondria [118].
The precise role of DNA2 and specific requirements for its helicase and nuclease activities
for mitochondrial stability remain to be experimentally determined.
Replication of mtDNA is mediated by a set of nuclear-encoded proteins. Interest-
ingly, autosomal dominant mutations affecting key components of this mtDNA replica-
tion machinery, including Pol γ and Twinkle have been linked to mitochondrial myopa-
thy [137,138]. Disease-causing mutations are also found in genes affecting replication
progression by maintaining mitochondrial dNTP pools [137]. Modeling of mitochondrial
myopathy-causing mutations within Twinkle and Pol γ demonstrated that mtDNA dele-
tions are associated with stalled replication intermediates [139,140]. As mentioned above,
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DNA2 localizes to mitochondria, where it accumulates further under replication-stress
conditions [118,119]. Although differences exist between nuclear and mitochondrial DNA
replication, chicken-foot structures such as those counteracted by DNA2 in the nucleus
have been detected within mtDNA after induction of replication stress [141]. In light of
the intimate links between mtDNA replication progression, mtDNA deletion, and mito-
chondrial myopathy, it is tempting to speculate that DNA2 might mediate RF recovery
in mitochondria in much the same way as in the nucleus, and that perturbations of this
function result in mtDNA deletions and mitochondrial disease.
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been seen in some cancer types in human (reviewed in [148]). Whether these mutations 
drive genome instability and contribute to tumorigenesis is currently unclear and will re-
quire a better understanding of the impact each individual mutation might have on DNA2 
function. On the other hand, DNA2 amplification and over-expression has been reported 
for a range of cancers including breast, pancreatic, and colorectal cancer [17,21,148–150]. 
This suggests that DNA2 could play a role in supporting cancer-cell proliferation, most 
likely through its ability to offset replication stress. 
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Cancer cells experience greater levels of replication stress compared to healthy cells. 
Oncogene activation drives cells into S phase with abnormal replication timing, imbal-
ances in origin of replication activity, increased conflicts between replication and tran-
scription, and inappropriate dNTP pools. As a consequence, RF progression is chronically 
impaired, and genome damage arising from chromosome underreplication is frequent 
[151–153]. Increased expression of DNA2 could therefore reflect an adaptation of cancer 
cells that helps them cope with elevated levels of endogenous replication stress and in-
creased requirements for RF recovery and DNA repair. In support of this notion, elevated 
DNA2 levels have been shown to correlate with a poor prognosis for breast cancer patients 
and stemness of cancerous cells in colorectal cancer [149,150]. Experimentally, DNA2 has 
been shown to promote cancer cell survival following overexpression of H-RAS or Cyclin 
E, suggesting a role for DNA2 in overcoming oncogene-induced replication stress [17]. 
4.2.2. Targeting DNA2 as an Anti-Cancer Strategy 
There is an increasing realization that endogenous replication stress represents an 
Achilles heel in cancer. While intrinsic replication stress may fuel tumorigenesis through 
the accumulation of cancer-promoting mutations, there is also the potential of exploiting 
it as a weapon against cancer cells. Hence, depriving cancer cells of key replication stress 
response factors may affect catastrophic genome damage and cell-cycle arrest. The poten-
tial for achieving this type of clinical synthetic lethality is exemplified by inhibitors tar-
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4.1.2. Seckel Syndrome
Seckel syndrome is an autosomal recessive disorder characterized by intrauterine
gr wth retardation, low birth weight, dwarfism, and icroceph ly [142]. Several Seckel syn-
drome patients with causative mutations in DNA2 have been des ribed [10,11]. Three out
of the four mapped mutations are intronic mutation that ause a reduction in the levels of
wild-type DNA2 and/or expression of incorrectly spliced transcripts (Figure 5). Interest-
ingly, p tients with mitoch ndrial myopathy, who are predicted to have reduced levels
of wild-type DNA2 protein, did not show Seckel-like features [136]. Further analyses are
required to det rmine wheth r the tru cated DNA2 transcripts in various patients are
stably expressed and how levels of r sidual wild-type DNA2 may relate to these distinct
diso ders. Among DNA2-S ckel pat ents, an individual wit an intronic mutation in one
allele, and a helicase-domain mutation near the ATP-binding site (DNA2 T665A) in the
other, has been identified. This patient presented with the most severe reduction in head
circumference and body height [11]. The DNA2 T665A mutation can be expected to have
a severe and specific effect on the ATPase/helicase activity, providing a tentative link
between Seckel syndrome and RF recovery, a function that clearly requires DNA2 helicase
activity in vivo.
Like mitochondrial myopathy, Seckel syndrome is genetically heterogeneous and
disease mutations affect groups of genes with roles in DNA replication/repair (ATR, DNA2,
CTIP, NSMCE2, and TRAIP) and segregation of the replicated genome into daughter cells
(CEP63, CEP152, CENPJ, NIN, and NSMCE2). When these processes are compromised,
cell proliferation is severely hampered, providing an explanation for growth defects asso-
ciated with Seckel syndrome. Some Seckel syndrome genes suggest striking parallels to
DNA2′s function in RF recovery and replication completion. For example, ubiquitin ligase
TRAIP promotes the completion of chromosomal replication and segregation by mediating
the clearance of replication obstacles in S phase and removal of the replication machinery
from sister chromatids in mitosis [143,144]. Similarly, DONSON, mutated in Seckel-like
disease, plays a key role in RF stability and replication completion [145–147]. By extension,
impaired RF recovery, incomplete DNA replication, and the resulting cell-proliferation
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defects in the absence of fully functional DNA2 [16,68,117] provide a potential explanation
for the involvement of DNA2 mutations in primordial dwarfism.
4.2. DNA2 as a Potential Anti-Cancer Target
From yeast to human, Dna2DNA2 is required to drive chromosomal replication to
completion. Consequently, when Dna2DNA2 is impaired, depleted, or lost, underreplication
ensues and results in the type of chromosome segregation problems and chromosomal
aberrations frequently seen in cancer cells [15–17,28,45,84,117,119]. DNA2+/− mice exhibit
genome instability and a higher incidence of cancer, suggesting that DNA2 haploinsuffi-
ciency drives malignant transformation [8]. Significant levels of DNA2 mutations have been
seen in some cancer types in human (reviewed in [148]). Whether these mutations drive
genome instability and contribute to tumorigenesis is currently unclear and will require a
better understanding of the impact each individual mutation might have on DNA2 function.
On the other hand, DNA2 amplification and over-expression has been reported for a range
of cancers including breast, pancreatic, and colorectal cancer [17,21,148–150]. This suggests
that DNA2 could play a role in supporting cancer-cell proliferation, most likely through its
ability to offset replication stress.
4.2.1. DNA2 Promotes the Survival of Cancer Cells with Elevated Levels of
Replication Stress
Cancer cells experience greater levels of replication stress compared to healthy cells.
Oncogene activation drives cells into S phase with abnormal replication timing, imbalances
in origin of replication activity, increased conflicts between replication and transcription,
and inappropriate dNTP pools. As a consequence, RF progression is chronically impaired,
and genome damage arising from chromosome underreplication is frequent [151–153].
Increased expression of DNA2 could therefore reflect an adaptation of cancer cells that
helps them cope with elevated levels of endogenous replication stress and increased
requirements for RF recovery and DNA repair. In support of this notion, elevated DNA2
levels have been shown to correlate with a poor prognosis for breast cancer patients and
stemness of cancerous cells in colorectal cancer [149,150]. Experimentally, DNA2 has been
shown to promote cancer cell survival following overexpression of H-RAS or Cyclin E,
suggesting a role for DNA2 in overcoming oncogene-induced replication stress [17].
4.2.2. Targeting DNA2 as an Anti-Cancer Strategy
There is an increasing realization that endogenous replication stress represents an
Achilles heel in cancer. While intrinsic replication stress may fuel tumorigenesis through
the accumulation of cancer-promoting mutations, there is also the potential of exploiting it
as a weapon against cancer cells. Hence, depriving cancer cells of key replication stress
response factors may affect catastrophic genome damage and cell-cycle arrest. The potential
for achieving this type of clinical synthetic lethality is exemplified by inhibitors targeting
the replication stress response kinases ATR and CHK1, which have reached clinical-trial
stage [154]. Enzyme effectors of the replication stress response and RF recovery, includ-
ing DNA2, may be equally well-suited drug targets for anti-cancer therapy [155].
Working on this premise, two small-molecule DNA2 inhibitors (DNA2i) have been
identified [20,21]. NSC-105808 (6-amino-7-bromoquinoline-5,8-dione) was shown to inhibit
the nuclease activity of DNA2 and restrict cancer cell proliferation to a greater extent
compared to non-transformed control cells [21]. Various cell types were sensitized to
NSC-105808 through oncogene expression (H-RAS, K-RAS, or human papillomavirus E6
and E7), suggesting that DNA2i may have the potential to act in a broad range of cancers
characterized by endogenous replication stress. Inhibitor studies have also focused on
combining DNA2i with treatments that further perturb RF progression. Inhibitor C5 (4-
hydroxy-8-nitroquinoline-3-carboxylic acid) was demonstrated to interfere with DNA2′s
ability to bind DNA, thus impacting both the helicase and nuclease activity of DNA2 [20].
Co-treatment of cells with C5 and exogenous replication stress acted to synergistically
reduce cell viability. Similarly, C5 and PARP inhibitors acted synergistically to inhibit cancer
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cell growth [20]. Poly(ADP-ribosyl)ation mediated by PARPs is a key posttranslational
modification for DNA repair and the recovery of stalled RFs [156–158]. Synergy between
DNA2 and PARP inhibitors would be consistent with a model where DNA2 counteracts
RF reversal, and if this is inhibited, PARP becomes critical for controlled chicken-foot
formation, processing, and RF restart.
The identification of small-molecule inhibitors of DNA2 is an exciting develop-
ment [20,21]. Although DNA2 is essential in healthy cells, the available data suggests
that there may be a therapeutic window large enough to titrate DNA2i for selective killing
of the more vulnerable cancer cells with elevated replication stress levels, while sparing
healthy cells. In addition, certain cancers may be further sensitized to DNA2 inhibition on
account of pre-existing mutations. This is exemplified by results showing greater efficacy
of DNA2i in killing cells harboring a gain-of-function mutant of p53 expressed in many
cancers [159]. These findings expand the potential of DNA2 inhibition for cancer therapy
and may help to stratify patients most likely to benefit from DNA2i treatment. Based on
the functional interplay between Dna2 and Holliday junction resolvase Yen1 in budding
yeast [74,75], it would be interesting to determine whether cancer cells that escape DNA2i
might be susceptible to targeted inhibition of one of the junction-resolving nucleases known
to target replication intermediates in human cells [78].
5. Concluding Remarks and Future Perspective
The Dna2DNA2 nuclease-helicase has been implicated in a variety of DNA metabolic
processes including OFP, DSB end-resection, RF recovery, and the pathological hyperresec-
tion of de-protected stalled RFs. It follows that the interpretation of cellular phenotypes
and human disease syndromes associated with loss of Dna2DNA2 function is inherently
difficult. Each observed defect could potentially have complex molecular underpinnings
involving multiple pathways. However, there are clearly common themes of incomplete
chromosomal replication, replication-stress sensitivity, and ineffective recovery of stalled
RFs associated with perturbations of Dna2DNA2 across organisms. The involvement of
DNA2 in mitochondrial myopathy and Seckel syndrome are consistent with a defect in
replication progression within the mitochondrial and nuclear genomes, and small-molecule
DNA2i successfully impair RF recovery to generate synthetic lethality in cancer cells with
endogenous replication stress. Thus, despite the complexity surrounding the multi-faceted
capabilities of Dna2DNA2, a unifying view is emerging around a central role of Dna2DNA2
in the processing and recovery of stalled RFs. This role is essential in yeast and provides
a plausible framework to rationalize why DNA2 is indispensable for mammalian cell
proliferation and human health.
Is it all about RFs? Certainly not. Dna2DNA2 contributes to chromosome break repair
by integrating with the DSB end-resection machinery. At least in yeast, a strong case has
been made for its participation in OFP. Although a major role for Dna2DNA2 in OFP has
not transpired in vitro or in vivo, its ability to degrade RPA-covered ssDNA expands the
repertoire of substrates that can be processed in cells during lagging-strand maturation.
Similarly, the versatile Dna2DNA2 nuclease-helicase is likely to be employed in further DNA
repair processes. Nonetheless, the most critical activity of Dna2DNA2 appears to be at stalled
RFs. In the future, it will be important to define more precisely the actions of Dna2DNA2 that
counteract RF reversal, resolve fully-fledged chicken-foot intermediates, allow stalled RFs
to resume DNA synthesis, limit recombination-based restart, and/or promote RF fusion.
These processes are critical for the completion of chromosomal replication across species.
A better mechanistic understanding of Dna2DNA2 and its interplay with other factors will
be key to inform the ongoing efforts to develop DNA2 as a target for anti-cancer therapy.
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